Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | -2M | -1M | 0 | 0 |
| Operating Income | -94M | -98M | -85M | -68M | -27M |
| EBITDA | -92M | -89M | -84M | -68M | -27M |
| Net Income | -90M | -90M | -79M | -69M | -27M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.79
+5.29% today
1Y Change
+28.78%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PepGen Inc. (PEPG) is a Healthcare stock with a market cap of $120.00M and listed on NASDAQ. The stock last traded around $1.79 and up 28.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +25.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +25.6%, free cash flow +1.2% with operating margin 0.0% and ROIC -56.9%. Stock Foundry combines PEPG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PEPG
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PEPG Max Drawdown
-81.17%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PEPG and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$27.3M
+60.5% YoY
Free Cash Flow
-$23.1M
+63.3% YoY
Revenue Growth
+0.0%
EPS Growth
+25.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | -2M | -1M | 0 | 0 |
| Operating Income | -94M | -98M | -85M | -68M | -27M |
| EBITDA | -92M | -89M | -84M | -68M | -27M |
| Net Income | -90M | -90M | -79M | -69M | -27M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 61M | 49M | 81M | 182M | 133M |
| Total Assets | 174M | 151M | 143M | 217M | 144M |
| Total Liabilities | 26M | 32M | 35M | 38M | 11M |
| Shareholder Equity | 147M | 119M | 108M | 180M | 133M |
| Total Debt | 17M | 19M | 20M | 25M | 0 |
| Net Debt | -44M | -31M | -61M | -157M | -133M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
23M
+61.9% YoY
Capital Expenditures
500K
+86.7% YoY
Free Cash Flow
23M
+63.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-75.7%
Debt / Equity
0.12x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.